Actively Recruiting
Phase 3 Study of Chemotherapy Regimens for Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
Led by Children's Oncology Group · Updated on 2026-08-25
205
Participants Needed
181
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial studies very low-risk and low-risk fusion-negative rhabdomyosarcoma, a type of soft tissue cancer, focusing on maintaining good outcomes while reducing therapy burden. It also evaluates how molecular risk classification can guide treatment and examines intensified therapy for tumors with specific DNA mutations. The study is a phase III clinical trial led by the Childrens Oncology Group. Participants receive one of several chemotherapy regimens based on their risk group and mutation status. Very low-risk patients get vincristine and dactinomycin every 21 days for 8 cycles. Low-risk patients receive vincristine, dactinomycin, and cyclophosphamide for 4 cycles, followed by vincristine and dactinomycin for 4 more cycles. Patients with specific mutations switch to an intensified regimen involving vincristine, dactinomycin, and cyclophosphamide for 12-13 cycles. Radiation therapy may be given during cycle 5 if needed. Throughout the study, participants undergo CT scans, MRI, bone scans, PET scans, and tumor biopsies for evaluation. Blood and tissue samples are collected at multiple points for future research. Researchers monitor failure-free survival and overall survival over several years, while also assessing the feasibility of central molecular risk testing. The total study duration and follow-up extend up to five years.
CONDITIONS
Brief Title
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here